Last reviewed · How we verify

Charitable Union for the Research and Education of Peyronie's Disease — Portfolio Competitive Intelligence Brief

Charitable Union for the Research and Education of Peyronie's Disease pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Control - Crossover to CCH Control - Crossover to CCH marketed Collagenase enzyme Collagen (types I and III) Urology / Sexual Medicine
CCH administration CCH administration marketed Collagenase enzyme Collagen I and III Urology / Sexual Health

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. DMR Research, PLLC · 1 shared drug class
  2. Hospital for Special Surgery, New York · 1 shared drug class
  3. Indiana Hand to Shoulder Center · 1 shared drug class
  4. Luxurgery · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Charitable Union for the Research and Education of Peyronie's Disease:

Cite this brief

Drug Landscape (2026). Charitable Union for the Research and Education of Peyronie's Disease — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/charitable-union-for-the-research-and-education-of-peyronie-s-disease. Accessed 2026-05-17.

Related